SCHEMBL19782730

SCHEMBL19782730

COCOc1ccc2occc2c1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 5/20 0.43
CYP1B1 Q16678 4/20 0.43
CYP1A2 P05177 3/20 0.43
KCNA3 P22001 3/20 0.42
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 4/20 0.41
CYP3A4 P08684 4/20 0.41
CYP2D6 P10635 3/20 0.41
TSHR P16473 3/20 0.41
CYP2C19 P33261 3/20 0.41
HSD17B10 Q99714 3/20 0.41
ADORA3 P0DMS8 2/20 0.41
CYP2C9 P11712 2/20 0.41
PGR P06401 1/20 0.41
CYP2A6 P11509 1/20 0.41
KCNA2 P16389 1/20 0.41
MAOA P21397 1/20 0.41
HTR2A P28223 4/20 0.41
HTR2C P28335 4/20 0.41
HTR2B P41595 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28792214 0.77 KCNA3 (0.56) KCNA3ALDH1A1KDM4ECYP3A4CYP2A6
SCHEMBL29679112 0.77 KCNA3 (0.56) KCNA3ALDH1A1KDM4ECYP3A4CYP2A6
SCHEMBL21395428 0.74 CYP1A1 (0.45) CYP1A1CYP1B1CYP1A2KCNA3ALDH1A1
SCHEMBL2046713 0.72 CYP1A1 (0.47) CYP1A1CYP1B1CYP1A2KCNA3ALDH1A1
SCHEMBL19783161 0.71 KDM4E (0.33) KDM4ECYP3A4CYP2D6TSHRCYP2C19
SCHEMBL19783244 0.70 KCNA3 (0.55) CYP1A1CYP1B1CYP1A2KCNA3ALDH1A1
SCHEMBL954825 0.70 CYP1A1 (0.48) CYP1A1CYP1B1CYP1A2KCNA3ALDH1A1
SCHEMBL30973495 0.70 CYP1A1 (0.33) CYP1A1CYP1B1CYP1A2KCNA3ALDH1A1
SCHEMBL8354843 0.68 HTR2A (0.47) CYP1A1CYP1B1CYP1A2KCNA3ALDH1A1
SCHEMBL30231369 0.67 MAOA (0.34) CYP1A1KCNA3KDM4ECYP3A4ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109689647-B Bicyclic heteroaryl substituted compounds 百时美施贵宝公司 2023-01-20 CN disclosed
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-06-03 US disclosed
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BISTOL MYERS SQUIBB COMPANY (US) 2019-09-26 US disclosed
WO-2018013774-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292176-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, PF4 CYP1A1 196/4885CYP1B1 167/4885CYP1A2 200/4885
US-20210163465-A1 BICYCLIC HETEROARYL SUBSTITUTED COMPOUNDS F2, F2RL3, F12 CYP1A1 164/4885CYP1B1 148/4885CYP1A2 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.